GNLX Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Genelux Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.55 |
| 52 Week High | US$16.60 |
| 52 Week Low | US$1.60 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | 17.51% |
| 1 Year Change | -77.03% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -58.54% |
Recent News & Updates
Genelux: H2 2025 PRROC Data Is A Major Inflection Point
Oct 31We're Keeping An Eye On Genelux's (NASDAQ:GNLX) Cash Burn Rate
Aug 24
Shareholder Returns
| GNLX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 8.1% | 2.5% | 2.2% |
| 1Y | -77.0% | 16.1% | 31.6% |
Return vs Industry: GNLX underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: GNLX underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| GNLX volatility | |
|---|---|
| GNLX Average Weekly Movement | 15.1% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GNLX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GNLX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 24 | Tom Zindrick | www.genelux.com |
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer.
Genelux Corporation Fundamentals Summary
| GNLX fundamental statistics | |
|---|---|
| Market cap | US$86.96m |
| Earnings (TTM) | -US$27.66m |
| Revenue (TTM) | US$8.00k |
Over9,999x
P/S Ratio-3.1x
P/E RatioIs GNLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GNLX income statement (TTM) | |
|---|---|
| Revenue | US$8.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$8.00k |
| Other Expenses | US$27.67m |
| Earnings | -US$27.66m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.81 |
| Gross Margin | 100.00% |
| Net Profit Margin | -345,750.00% |
| Debt/Equity Ratio | 0% |
How did GNLX perform over the long term?
See historical performance and comparison